Can I Take Creatine with Praluent (Alirocumab)?

What Is Alirocumab (Praluent) and Why Is It Prescribed?

Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, the drug keeps more LDL receptors on liver cell surfaces, accelerating clearance of LDL particles from blood. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond statins [1].

How Alirocumab Is Metabolized

Monoclonal antibodies like alirocumab are not metabolized by cytochrome P450 (CYP) enzymes. They follow two clearance pathways: a target-mediated pathway (binding to PCSK9 and being internalized by cells) and a non-specific proteolytic degradation pathway shared by all IgG antibodies [2]. This metabolic profile means that drugs or supplements affecting CYP3A4, CYP2C9, or P-glycoprotein have no mechanistic ability to alter alirocumab exposure. Creatine does not touch either of alirocumab's clearance pathways.

Clinical Efficacy Context

The ODYSSEY LONG TERM trial (N=2,341) showed alirocumab 150 mg every 2 weeks reduced LDL-C by a mean of 61.9% from baseline at 24 weeks versus placebo [3]. The ODYSSEY OUTCOMES trial (N=18,924) later demonstrated a 15% relative risk reduction in major adverse cardiovascular events (MACE) over a median 2.8 years [4]. Patients on alirocumab are typically high-risk individuals in whom accurate renal monitoring matters, which is exactly where creatine supplementation creates complexity.

What Is Creatine and How Does the Body Handle It?

Creatine is a naturally occurring compound synthesized from glycine, arginine, and methionine, primarily in the liver and kidneys. Skeletal muscle stores approximately 95% of the body's creatine pool as free creatine and phosphocreatine [5]. Oral supplementation with 3 to 5 g/day raises total muscle creatine content by 10 to 40% above baseline, with loading protocols of 20 g/day for 5 to 7 days producing faster saturation [6].

The Creatinine Artifact Problem

Creatine is non-enzymatically converted to creatinine at a rate proportional to total body creatine stores. Supplementing creatine raises serum creatinine independent of any change in actual kidney filtration. A randomized crossover study in healthy adults (N=18) found that 20 g/day creatine for 5 days elevated serum creatinine by a mean of 0.24 mg/dL (roughly 20% from baseline) without any measurable change in inulin clearance, the gold-standard GFR measurement [7]. A separate trial using 5 g/day for 12 weeks in resistance-trained men produced a sustained 10 to 15% creatinine elevation throughout supplementation [8].

This matters because most clinicians ordering a basic metabolic panel or comprehensive metabolic panel during Praluent follow-up will see creatinine as their primary renal marker. A patient with a baseline creatinine of 1.0 mg/dL could appear to have a creatinine of 1.2 to 1.3 mg/dL purely from creatine supplementation, a value that might trigger concern or unnecessary nephrology referral.

Creatine and Actual Kidney Function

The evidence on long-term creatine safety in healthy kidneys is reassuring. A systematic review and meta-analysis of 15 randomized controlled trials (N=548) published in the Journal of Renal Nutrition found no significant effect of creatine supplementation on actual glomerular filtration rate, urinary albumin excretion, or other markers of kidney injury in individuals with normal baseline renal function [9]. The International Society of Sports Nutrition (ISSN) position stand states creatine monohydrate is safe for healthy individuals at doses up to 30 g/day for up to 5 years [6]. However, the evidence base in people with pre-existing CKD or significantly reduced GFR remains thin, and caution is warranted in that population.

Does Creatine Interact Pharmacokinetically with Praluent?

No. The question of whether creatine changes how alirocumab behaves in the body has a clear mechanistic answer: it cannot. Creatine is absorbed in the small intestine via the creatine transporter (SLC6A8), distributed to muscle tissue, and converted to creatinine for renal excretion [5]. None of these steps overlap with the proteolytic degradation pathway that clears alirocumab.

No CYP450 Involvement on Either Side

Creatine does not induce or inhibit any major CYP450 enzyme at supplemental doses. Alirocumab does not require CYP450 for clearance. The FDA prescribing information for Praluent explicitly states no formal drug interaction studies were conducted because the biologic nature of the drug makes CYP-mediated interactions mechanistically implausible [1]. Supplements that do affect CYP enzymes (St. John's Wort, for instance) are the class of concern for small-molecule drugs, not for monoclonal antibodies.

No Pharmacodynamic Overlap

Alirocumab acts on PCSK9 in hepatic tissue. Creatine acts on the phosphagen energy system in skeletal muscle. There is no shared receptor, transporter, or downstream signaling pathway between these two mechanisms. A pharmacodynamic interaction would require both agents to affect the same physiological target, which they do not [2].

The Renal Monitoring Issue: Where Clinical Judgment Is Required

This is the area that warrants the most attention for a patient taking both agents. Alirocumab prescribers typically monitor a lipid panel at 4 to 8 weeks after initiation, then periodically thereafter [1]. Many also monitor a basic metabolic panel to assess renal function, particularly in older patients or those with hypertension or diabetes who are at elevated cardiovascular risk.

Why Cystatin C Is the Better Marker

Cystatin C is a low-molecular-weight protein filtered freely at the glomerulus. Unlike creatinine, its serum concentration is not affected by muscle mass, meat intake, or creatine supplementation. A 2012 CKD-EPI equation incorporating both creatinine and cystatin C (CKD-EPI Cr-CysC) showed better accuracy for GFR estimation than creatinine alone in a validation cohort of 3,939 individuals [10]. Patients on creatine supplementation who are also on Praluent should request cystatin C-based eGFR testing rather than standard creatinine-based eGFR when renal function monitoring is performed.

Practical Lab Interpretation

A creatinine value elevated by creatine supplementation will not affect alirocumab dosing directly since alirocumab has no renal dose adjustment in its FDA label [1]. But the artifact can lead to downstream decisions: dose reductions of renally cleared co-medications, unnecessary imaging, or premature discontinuation of creatine (which is otherwise safe). Letting your prescriber know you are taking creatine before any blood draw is the single most actionable step a patient can take.

Monitoring Framework: Creatine Plus Alirocumab

The table below summarizes what to monitor, how often, and which lab test to request:

| Parameter | Test | Frequency | Note | |---|---|---|---| | LDL cholesterol | Fasting lipid panel | 4 to 8 weeks after dose change, then every 6 to 12 months | Primary efficacy marker for Praluent | | Renal function | Cystatin C-based eGFR (CKD-EPI Cr-CysC) | Annually, or per prescriber | Preferred over creatinine alone during creatine supplementation | | Serum creatinine | BMP or CMP | As ordered | Interpret with knowledge of creatine use; expect 10 to 30% elevation | | Urinary albumin-to-creatinine ratio | Spot urine | Annually in patients with diabetes or hypertension | Not affected by creatine; reliable kidney injury marker | | Muscle symptoms | Clinical assessment | At each visit | Creatine does not cause myopathy; distinguish from statin-related myalgia |

Who Should Be Cautious or Avoid Creatine While on Praluent?

Most patients on Praluent can use creatine without issue, but specific subgroups need closer evaluation.

Patients with CKD Stage 3 or Higher

The National Kidney Foundation defines CKD stage 3 as eGFR 30 to 59 mL/min/1.73 m² [11]. In this population, even a modest rise in creatinine load could stress already-reduced tubular handling capacity. The thin evidence base for creatine in CKD means the benefit-risk calculation shifts. Patients with stage 3+ CKD should discuss creatine use explicitly with their nephrologist before starting, regardless of Praluent use.

Patients on Concomitant Nephrotoxic Agents

Some high-cardiovascular-risk patients take NSAIDs, contrast agents for imaging, or aminoglycoside antibiotics. Those agents do carry renal risk. Adding creatine's creatinine artifact to a patient already being monitored for nephrotoxicity from another drug can cloud the clinical picture further [9].

Patients with Baseline Creatinine Above 1.4 mg/dL

A creatinine already at 1.4 mg/dL elevated by 20 to 30% reaches 1.68 to 1.82 mg/dL, values that may breach thresholds triggering clinical action in many institutional protocols. These patients should shift to cystatin C monitoring proactively, rather than after confusion has already occurred.

What Doses of Each Agent Are We Talking About?

Alirocumab Dosing

The FDA-approved starting dose of alirocumab is 75 mg subcutaneous injection every 2 weeks. Prescribers may titrate to 150 mg every 2 weeks if the LDL-C response at 8 to 12 weeks is insufficient [1]. An alternative regimen of 300 mg every 4 weeks is also approved and may improve adherence. No renal dose adjustment exists in the label.

Creatine Dosing in the Supplement Literature

The most-studied protocol uses a loading phase of 20 g/day in four 5 g doses for 5 to 7 days, followed by a maintenance dose of 3 to 5 g/day [6]. The loading phase produces the sharpest creatinine artifact, so timing any routine blood work after the loading phase but before disclosing supplement use to the lab will produce the most misleading results. Patients who want to avoid lab confusion may skip the loading phase and use 3 to 5 g/day from the start, which saturates muscle creatine within 28 days and produces a more modest creatinine rise [6].

Statin Co-Administration: A Relevant Consideration

Most patients on Praluent are also on a statin. Statins are associated with myalgia in roughly 5 to 10% of users, and some patients use creatine hoping to preserve muscle mass or reduce exercise-related soreness while on statin therapy [12]. A 12-week double-blind RCT (N=54) published in the Journal of the International Society of Sports Nutrition found that creatine supplementation did not worsen statin-related muscle symptoms and did not raise creatine kinase beyond expected training-related ranges [13]. This is clinically relevant because a CK elevation in a statin user taking creatine needs careful interpretation: creatine from hard training raises CK without indicating myopathy, while true statin-induced myopathy (CK greater than 10 times the upper limit of normal) is a different magnitude of elevation [12].

The American College of Cardiology/American Heart Association 2022 Guideline on the Management of Blood Cholesterol states: "Patients with statin-associated muscle symptoms should be evaluated to exclude other conditions that might predispose them to muscle symptoms" [14]. Creatine supplementation is one such condition that alters baseline CK interpretation and should be disclosed.

What to Tell Your Prescriber

Disclosing creatine supplementation to any clinician managing your Praluent therapy takes roughly 30 seconds and prevents a cascade of unnecessary follow-up. Specifically, tell them:

• The dose you are taking (e.g., 5 g/day creatine monohydrate)
• How long you have been taking it
• Whether you recently completed a loading phase

Armed with this information, your prescriber can note it in your chart, order cystatin C alongside or instead of creatinine for renal assessments, and avoid misinterpreting an elevated creatinine as a sign of kidney injury.

The FDA MedWatch system does not list creatine as a substance with a known interaction with alirocumab, and the Praluent prescribing information contains no language restricting creatine or any other supplement affecting creatinine [1]. The concern is entirely about accurate lab interpretation, not drug safety.

Evidence Quality and Gaps

The evidence supporting the absence of a pharmacokinetic interaction between creatine and alirocumab is mechanistic and high-quality. No direct head-to-head clinical trial has studied this combination, but the mechanistic rationale is strong enough that such a trial is unlikely to be designed: monoclonal antibody clearance is simply not a pathway creatine can touch [2].

The evidence on long-term creatine safety in patients with established ASCVD is less developed. Most creatine safety trials enrolled healthy athletes or older adults without significant cardiovascular comorbidity. The ODYSSEY population would be a clinically relevant group to study prospectively, but no such data are currently published [4].

A 2021 Cochrane review on dietary supplements and cardiovascular outcomes did not identify creatine as a substance with direct cardiovascular risk in standard supplemental doses [15]. For patients with ASCVD, the priority remains strict adherence to Praluent, statin therapy if tolerated, and lifestyle modification per AHA/ACC guidelines [14].

Practical Steps if You Are Already Taking Both

1. Disclose creatine use to your Praluent prescriber at your next visit or via the patient portal before your next lab draw.
2. Request cystatin C-based eGFR at your next renal monitoring appointment. Ask specifically for CKD-EPI Cr-CysC if your institution offers it [10].
3. If you are in a loading phase (20 g/day), schedule any non-urgent blood work for after the loading phase ends, ideally 7+ days after returning to a 3 to 5 g/day maintenance dose. Creatinine will still be elevated but by a smaller and more predictable margin.
4. Continue your Praluent injections on schedule. There is no timing, spacing, or dose adjustment needed for the biologic itself.
5. If you have CKD stage 3 or higher, discuss whether creatine offers enough benefit to justify the added lab complexity in your specific case.

The ODYSSEY OUTCOMES trial documented that consistent alirocumab use over 2.8 years reduced the risk of fatal or non-fatal MI by 14% (HR 0.86; 95% CI 0.76 to 0.98; P<0.05) [4]. Interrupting Praluent therapy over a creatinine artifact that could have been anticipated and explained is a clinical outcome worth avoiding.